Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	5.83T +99.1%
Revenue (ttm)	1.55T +3.5%
Net Income	169.55B +39.8%
EPS	13,362.00 +39.7%
Shares Out	12.68M
PE Ratio	34.43
Forward PE	33.10
Dividend	1,250.00 (0.26%)
Ex-Dividend Date	Mar 30, 2026

Volume	142,654
Average Volume	84,606
Open	481,500
Previous Close	483,000
Day's Range	456,500 - 483,500
52-Week Range	247,000 - 647,000
Beta	0.62
RSI	35.92
Earnings Date	Apr 30, 2026

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,400
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2025, Hanmi Pharm.'s revenue was 1.55 trillion, an increase of 3.48% compared to the previous year's 1.50 trillion. Earnings were 169.55 billion, an increase of 39.76%.